Lisata shareholders approve all six proposals at 2024 annual meeting

LISATA THERAPEUTICS, INC.

Re-elected Class II directors Brown, Henson, and Mazzo; votes ranged from 3.15M to 3.26M for.
Approved 2018 Equity Plan amendment adding 600k shares and a 3-year evergreen clause (5% or board-set).
Approved ESPP increase from 68,333 to 113,333 shares; 3.06M for, 131k against.
Ratified Grant Thornton as auditor for FY2024; 3.71M for, 401k against, no broker non-votes.
Non-binding advisory vote on executive compensation passed with 3.09M for, 417k against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.